Belief BioMed BBM-D101 Gene Therapy Receives IND Clearance by National Medical Products Administration (NMPA)
Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA)...
New Drug Submission for AGAMREE (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy
Catalyst Pharmaceuticals has announced that Health Canada has accepted their New Drug Submission (NDS) for AGAMREE (vamorolone) with priority review status for treating Duchenne...
Genethon CEO Frederic Revah Announces GNT0004 Gene Therapy Will Provide Amazing Results for DMD (Duchenne Muscular Dystrophy)
The Chief Executive Officer of Genethon, Frederic Revah, made the announcement on the YouTube channel of AFM-Telethon that the GNT0004 gene therapy, which is...
U.S. Department of Defense Announces Duchenne Muscular Dystrophy Research Programs and Funding Opportunities for Fiscal Year 2025
We extend our deepest gratitude to the Members of Congress who fought to preserve Duchenne funding and to the Department of Defense for recognizing...
Three Ongoing Clinical Trials of Elevidys Gene Therapy Temporarily Halted in Europe
Three ongoing clinical trials of ELEVIDYS (delandistrogene moxeparvovec-rokl), a gene therapy developed by Sarepta and marketed by Roche, have been temporarily halted by the...